Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Effects of an Oral Growth Hormone Secretagogue in Older Adults

Open access
White, Heidi K., Petrie, Charles D., Landschulz, William, MacLean, David, Taylor, Ann, Lyles, Kenneth, Wei, Jeanne Y., Hoffman, Andrew R., Salvatori, Roberto, Ettinger, Mark P., Morey, Miriam C., Blackman, Marc R., Merriam, George R., for the Capromorelin Study Group · 2009 · The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: GH secretion declines with age, possibly contributing to reduced muscle mass, strength, and function. GH secretagogues (GHS) may increase muscle mass and physical performance. OBJECTIVES/DESIGN: We conducted a randomized, double-masked, placebo-controlled, multicenter study to investigate the hormonal, body composition, and physical performance effects and the safety of the orally active GHS capromorelin in older adults with mild functional limitation. INTERVENTION/PARTICIPANTS: A total of 395 men and women aged 65-84 yr were randomized for an intended 2 yr of treatment to four dosing groups (10 mg three times/week, 3 mg twice a day, 10 mg each night, and 10 mg twice a day) or placebo. Although the study was terminated early according to predetermined treatment effect criteria, 315 subjects completed 6 months of treatment, and 284 completed 12 months. RESULTS: A sustained dose-related rise in IGF-I concentrations occurred in all active treatment groups. Each capromorelin dose prompted a rise in peak nocturnal GH, which was greatest with the least frequent dosing. At 6 months, body weight increased 1.4 kg in subjects receiving capromorelin and decreased 0.2 kg in those receiving placebo (P = 0.006). Lean body mass increased 1.4 vs. 0.3 kg (P = 0.001), and tandem walk improved by 0.9 sec (P = 0.02) in the pooled treatment vs. placebo groups. By 12 months, stair climb also improved (P = 0.04). Adverse events included fatigue, insomnia, and small increases in fasting glucose, glycosylated hemoglobin, and indices of insulin resistance. CONCLUSIONS: In healthy older adults at risk for functional decline, administration of the oral GHS capromorelin may improve body composition and physical function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2008-0632

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 171

Metadata

Authors
White, H. K., Petrie, C. D., Landschulz, W., MacLean, D., Taylor, A., Lyles, K., Wei, J. Y., Hoffman, A. R., Salvatori, R., Ettinger, M. P., Morey, M. C., Blackman, M. R., Merriam, G. R., & for the Capromorelin Study Group
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2009-04-01
Volume
94
Issue
4
Pages
1198-1206
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2141361742
Cited by
171
References
15
FWCI
7.39
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of an Oral Growth Hormone Secretagogue in Older Adults. https://app.cochat.ai/papers/10.1210/jc.2008-0632
The paper
White, H. K., Petrie, C. D., Landschulz, W., MacLean, D., Taylor, A., Lyles, K., Wei, J. Y., Hoffman, A. R., Salvatori, R., Ettinger, M. P., Morey, M. C., Blackman, M. R., Merriam, G. R., & for the Capromorelin Study Group. (2009). Effects of an Oral Growth Hormone Secretagogue in Older Adults. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2008-0632

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.